Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Endometrial Cancer.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Iluzanebart is under clinical development by Vigil Neuroscience and currently in Phase I for Unspecified Neurologic Disorders.

ENB-105 is under development for the treatment of inflammatory bowel disease and immune checkpoint inhibitor colitis (ICI-Colitis). It is being developed based on eSTEM systems biology platform.

Semaglutide biosimilar is under clinical development by Leto Laboratories and currently in Phase II for Diabetes.

QL-401 is under clinical development by QLSF Biotherapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Refractory Multiple Myeloma.